---
title: The Role of Nitric Oxide Synthase in Circulating Progenitor Cell Function
nct_id: NCT00627068
overall_status: COMPLETED
sponsor: University of California, San Francisco
study_type: OBSERVATIONAL
primary_condition: Cardiovascular Disease
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00627068.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00627068"
ct_last_update_post_date: 2011-09-20
last_seen_at: "2026-05-12T06:03:33.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Role of Nitric Oxide Synthase in Circulating Progenitor Cell Function

**NCT ID:** [NCT00627068](https://clinicaltrials.gov/study/NCT00627068)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 60
- **Lead Sponsor:** University of California, San Francisco
- **Conditions:** Cardiovascular Disease
- **Start Date:** 2007-07
- **Completion Date:** 2010-12
- **CT.gov Last Update:** 2011-09-20

## Brief Summary

Our main hypothesis is that EPC function is impaired in some populations with high cardiovascular risk as a result of reduced eNOS-dependent NO production.

## Detailed Description

To determine if a correlation exists between EPC function and eNOS-dependent NO production in EPCs from populations with high versus low cardiovascular risk:

1. High and low cardiovascular risk subjects will be identified based on age or history of cardiovascular disease. Endothelial function will be measured by ultrasound.
2. EPCs will be isolated from peripheral blood of these subjects. EPC function will be assessed by measuring adhesion to endothelium, migration, proliferation, and differentiation, and compared to their expression and activity of eNOS.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Willing and able to give written informed consent and comply with study requirements
* Adult of 18 years or older
* Subjects willing to provide blood and tissue samples

Exclusion Criteria:

* Failure to give informed consent.
* Those unable to consent for themselves.
* Those who cannot read English.
* Patients on Viagra, Levitra, or Cialis
* Patients with malignant disease
* Patients with hematological abnormalities
* Patients with fevers of unknown origin
* Severe comorbidity or alcohol/drug dependence
* Women who are post-menopausal and on hormone replacement therapy, or premenopausal and on birth control pills (premenopausal women will be screened verbally and then by assay of LH and FSH levels in blood samples to identify women in the follicular phase of their menstrual cycle, to reduce variability)
```

## Arms

- **1** — High cardiovascular risk age over 61 years.
- **2** — Low Cardiovascular risk age over 61.
- **3** — High cardiovascular risk age over 25 but under 61.
- **4** — Low cardiovascular risk age over 25 under 61.

## Locations (1)

- UCSF, Department of Cardiology, San Francisco, California, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.ucsf, department of cardiology|san francisco|california|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00627068.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00627068*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*